Dying repeatedly is expected in a roguelite. Even so,The Persistence has an option for you to turn the difficulty down, but it warns you that the game was designed for you to die repeatedly and often. The games biggest issue is that it completely leans on this as the main way to extend its playtime. Make no mistake; this is a good game with an interesting premise and tight gameplay. It just shoots itself in the foot at times with arbitrary contrivances that seemingly exist to lengthen the ride.
The Persistencetells the story of the titular starcraft. Before the game starts, the entire crew dies horribly. Luckily, one of the crew members, named Serena, has her mind uploaded into the ships computer. She then uses the mind of another member, Zimri, to place into a clone body so that she can turn the ships vital systems back on to get them home.
Only, this is a survival-horror type roguelite, so things arent that simple. The same printer that creates Zimris clone body has gone haywire and created mindless killing machines that stalk the decks of the ship. As Zimri, youll need to navigate these dangers while restoring the ships systems. Every time Zimri dies, The Persistenceplaces her in another clone body and starts her back from the ships recovery deck.
There arent much in the way of cutscenes in The Persistence. There are brief ones at the beginning and end, plus there are three slightly different endings that you can go back and get if youd like. Most of the narrative elements are just from Zimri and Serena talking to one another. The dialogue is well-written and the voice acting is strong, so these bits of conversation add a lot of personality and context to the game. The game can either be played in first-person on your monitor or with VR headsets, as it was originally released via PlayStation VR. There isnt currently motion controller support, however.
The Persistence is broken up into five objectives, with four of these each taking place on one of the four main decks. Every time you enter a deck via teleporter, its layout is procedurally generated. Each of the objectives is highlighted with a green marker on your map and you simply need to get there and survive whatever hellishness the game throws at you. For instance, the first objective is to restart the ships stardrive. You just go to the appropriate section, sneak your way past enemies, and get the thing going again. Once you complete an objective, you then need to find the teleporter to the next deck.
I completed the first two of the games main four objectives in just a few hours, so I was expectingThe Persistence to be on the short side. However, the game doesnt show its true colors until deck three. If youve played Rogue Legacy or similar games, youre going to be very familiar with the core gameplay loop here. You go into an area that you are not capable of really surviving to collect resources which you bring back to the start and upgrade your character.
There are two resources in the game: fabrication credits and stem cells. Fab credits are used to create temporary and permanent equipment, while stem cells are used to print new clone bodies and for permanent character upgrades. Both are found scattered throughout the environment, but killing enemies will often have them drop credits while using your harvester to take their stem cells from behind them is the main way to get those.
Zimri has a lot of tools at her disposal in regards to dealing withThe Persistences rampant foes. The permanent character upgrades increase her health, melee damage, sneaking capabilities, and how much dark matter energy she has. Dark matter is used for both sensing the enemies around you for a couple of seconds and for teleporting. These two abilities can be improved by finding and implementing schematics that enemies drop. Or you can find them in supply crates with associated challenges. You can also improve the clone bodys default equipment, such as the harvester and their suit.
Youll find a few new bodies of crew members whose DNA can be harvested, too. Doing so will allow you to place Zimris mind in other bodies with various benefits. Its free to print Zimris body, but the others all cost stem cells. Zimri gets a discount at fabrication terminals on the ships decks, while others increase your loot, stem cells harvested, damage, or health.
As for weapons and items, different terminals print guns, melee weapons, grenades, and experimental items. These items are unlocked with Erebus tokens that youll find all over. They can also be upgraded with tokens, which drastically increases their price, even if the effectiveness of some isnt boosted in any tangible way. The weapons offer very few uses once printed. The guns give you practically no ammo and, even if you print a second one, itll cost just as much even if you only want the ammo.
I enjoyed myself a great deal during the first two decks. The subsequent two, while still fun a lot of the time, were much more painful. Getting through these two took me about double the time of the first couple and it was because damn near everything killed me in one hit. Once you complete an objective and get to a new deck, you can teleport to the one whose objective you just completed. This means that youll need to make your way back through that deck to get to the one where the next objective waits.
ButThe Persistence lives up to its name at this point. You need to spend hours scrounging for fab credits and harvesting stem cells to get your health up to respectable levels. And matters are complicated by how arbitrary and cheap many of the games systems are. Regardless of which body Zimris in, she cant run. Youre supposed to teleport to move quickly, sure, but it makes no sense for a human being to be unable to run when being chased by monsters. If you run out of a dark matter and a monsters close on your tail, youre probably just going to die.
To add insult to injury, while Zimri can carry every single weapon and experimental item at the same time, she can only use medkits as she finds them. She cant pick up a few to keep on her person just because it arbitrarily makes the game more difficult. Plenty ofThe Persistences mechanics defy logic in this manner solely to artificially increase the difficulty. It makes the game much more frustrating and time-consuming than it needs to be. But some of the enemy behavior is worse.
The Persistence partially bills itself as a bit of a stealth game, but there are some enemies you simply cant sneak past. One enemy walks around on all fours and just magically gets alerted to your presence regardless of if he can see or hear you. Another has no eyes and has to locate you through sound alone. But it can bizarrely only hear you when its facing you. Sometimes itll notice you and start shooting even if you werent making any noise or have your stealth up all the way. Teleporting is silent, so he shouldnt be able to track you once you move, but it somehow can.
Then theres the teleporting beam woman. Shes only vulnerable immediately after she shoots her beam at you, which takes several entire seconds to finish. You cant sneak up on her, as trying to harvest her from behind makes her teleport away. And, even if youre being as quiet and careful as you can, she randomly teleports around and will happen upon you no matter what.
Also, her beam locks you in place, so you cant move or teleport while being hit by it. For no reason. You need to deflect it with your force field. But the force field makes no sense either. You can only put it up for a second at a time to quickly block enemy attacks, but, when blocking the beam, it can stay up for way longer than usual just because. The shield also takes damage and needs to recharge. So, if youre beset upon by many foes and you run out of charge, you can no longer block, so you better have a lot of health.
Pouring stem cells into permanent upgrades is imperative for surviving these enemy encounters. And doing so massively pads the game. Overall, I enjoy playingThe Persistence, but the pacing issues will likely ruin it for some. I know I made it sound like a giant pain (which it certainly can be), but its also very satisfying to properly utilize your resources to do cool things like fight a hulking monster simply by teleporting behind it and harvesting its cells once you have enough dark matter to afford the cost of doing so.
The main game will likely take most people about 10 hours, but a campaign plus unlocks afterward that features even more upgrade levels and higher weapon tiers. Plus theres a mode that limits how many clones you can make, and even a permadeath one for masochists. Anyone that isnt massively turned off by how illogical The Persistencecan be can find a lot to like here. I just wish it didnt feel like it needed to pad itself out so much solely to extend its length.
Originally posted here:
The Persistence review Dead again - PC Invasion
- The therapeutic potential of stem cells - PubMed Central (PMC) - November 12th, 2024
- Stem Cell Therapy Market Is Projected To Achieve A Market Value Of USD 3.40 Bn. By 2030, Reflecting A Robus... - WhaTech - October 18th, 2024
- Doctor who provided ineffective stem cell therapies disciplined 6 years after investigation began - CBS Chicago - October 15th, 2024
- Study reveals the benefits and downside of fasting - Big Think - September 28th, 2024
- Tiny vesicles from umbilical cord blood may have therapeutic benefit - Parkinson's News Today - September 28th, 2024
- The Stem Cell Solution Review: Is This Program the Future of Anti-Aging and Recovery? - Enumclaw Courier-Herald - September 28th, 2024
- Cell and Gene Therapy Research To Benefit From New Stem Cell Collection Center - Technology Networks - September 25th, 2024
- Stem Cell Restore: A Full Review of Its Role in Promoting Regeneration and Vitality - Islands' Sounder - September 18th, 2024
- Is fasting good for you? A new study reveals some hidden risks and benefits of the practice - Business Insider India - August 31st, 2024
- Study reveals the benefits and downside of fasting - MIT News - August 27th, 2024
- Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB® Patent Related to the Treatment of Acute Pain - August 22nd, 2024
- Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Niclas Lindstedt - August 22nd, 2024
- PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins - August 22nd, 2024
- BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY... - August 22nd, 2024
- Eyenovia Announces Pricing of $5.14 Million Public Offering - August 22nd, 2024
- Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management... - August 22nd, 2024
- Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - August 22nd, 2024
- SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX® - August 22nd, 2024
- MDxHealth Reports Q2 and Half Year 2024 Results - August 22nd, 2024
- Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country - August 22nd, 2024
- Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of... - August 22nd, 2024
- Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility - August 22nd, 2024
- Certara to Participate in Upcoming Investor Conferences - August 22nd, 2024
- Orion Corporation: Managers’ transactions – Satu Ahomäki - August 22nd, 2024
- Bavarian Nordic Announces First Half 2024 Results - August 22nd, 2024
- BioCryst to Present at Upcoming Investor Conferences - August 22nd, 2024
- Zymeworks Announces Participation in Upcoming Investor Conferences - August 22nd, 2024
- MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update - August 14th, 2024
- Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - August 14th, 2024
- Shock Top and Gator Athletics Partner to Introduce First-Ever Craft Beer Sponsorship of the Florida Athletic Department - August 14th, 2024
- IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update - August 14th, 2024
- Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - August 14th, 2024
- Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders - August 14th, 2024
- Evaxion Announces Business Update and Second Quarter 2024 Financial Results - August 14th, 2024
- Galera Announces Board Approval of Complete Liquidation and Dissolution - August 14th, 2024
- Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update - August 14th, 2024
- Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - August 14th, 2024
- Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research - August 14th, 2024
- CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update - August 14th, 2024
- Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine - August 14th, 2024
- Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors - August 14th, 2024
- Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005 - August 14th, 2024
- Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic... - August 14th, 2024
- Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results - August 14th, 2024
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - August 14th, 2024
- Atsena Therapeutics Receives Rare Pediatric Disease Designation from the U.S. FDA for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis - August 14th, 2024
- Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates... - August 14th, 2024
- What Is Stem Cell Therapy? How Does It Work? - ThePrint - August 6th, 2024
- New Study Shows Short-Term Benefits of Stem Cell Therapy for MS Patients, But Long-Term Efficacy Remains Unclear - Managed Healthcare Executive - July 26th, 2024
- Cord Blood Awareness Month: Advantages of cord blood banking, things to keep in mind - Moneycontrol - July 10th, 2024
- Neural Stem Cell Plasticity: Advantages in Therapy for the Injured Central Nervous System - Frontiers - June 28th, 2024
- Harnessing benefits of stem cells for heart regeneration | ASU News - ASU News Now - June 21st, 2024
- 'Didn't know this would be possible': Autistic teen's mom on stem cell therapy benefits - WZTV - May 6th, 2024
- John Cleese says he's been spending 17,000 annually on stem cell therapy to 'buy a few extra years' - Yahoo News UK - April 24th, 2024
- Promethera Bets Liver-Derived Stem Cells Will Offer Benefits In NASH - Scrip - April 24th, 2024
- Stem Cell Therapies: Is This The Future Of Wellness? - Grazia USA - April 20th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
Recent Comments